In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Alumis Inc., with a price target of $44.00.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Thompson CFA is a top 100 analyst with an average return of 51.1% and a 75.37% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Cullinan Management, and Argenx Se.
In a report released on July 1, Wells Fargo also reiterated a Buy rating on the stock with a $51.00 price target.
Based on Alumis Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.74 million and a GAAP net loss of $93.05 million. In comparison, last year the company earned a revenue of $17.39 million and had a GAAP net loss of $98.96 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALMS in relation to earlier this year. Earlier this month, Sanam Pangali, the CLO of ALMS sold 5,000.00 shares for a total of $140,000.00.
